


Company Registration No. 06944607 (England and Wales)

EMESS BIOSCIENCES LIMITED
ABBREVIATED ACCOUNTS
FOR THE YEAR ENDED 30 JUNE 2014

FRIDAY



L45YWLTE

LD6

24/04/2015

#39

COMPANIES HOUSE

EMESS BIOSCIENCES LIMITED

CONTENTS

	Page
Abbreviated balance sheet	1
Notes to the abbreviated accounts	2 - 3

EMESS BIOSCIENCES LIMITED

ABBREVIATED BALANCE SHEET

AS AT 30 JUNE 2014

	Notes	2014 £	£	2013 £	£
Fixed assets					
Investments	2		145,080		145,080
Current assets					
Debtors		6		6	
Creditors: amounts falling due within one year		<u>(182,597)</u>		<u>(182,158)</u>	
Net current liabilities			<u>(182,591)</u>		<u>(182,152)</u>
Total assets less current liabilities			<u>(37,511)</u>		<u>(37,072)</u>
Capital and reserves					
Called up share capital	3		6		6
Profit and loss account			<u>(37,517)</u>		<u>(37,078)</u>
Shareholders' funds			<u>(37,511)</u>		<u>(37,072)</u>


For the financial year ended 30 June 2014 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

Directors' responsibilities:

- The members have not required the company to obtain an audit of its financial statements for the year in question in accordance with section 476;
- The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of financial statements.

These abbreviated financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies' regime.

Approved by the Board and authorised for issue on 9 March 2015



M J Sinclair
Director

Company Registration No. 06944607

EMESS BIOSCIENCES LIMITED

NOTES TO THE ABBREVIATED ACCOUNTS

FOR THE YEAR ENDED 30 JUNE 2014

1 Accounting policies

1.1 Accounting convention

The financial statements are prepared under the historical cost convention.

The company has taken advantage of the exemption in Financial Reporting Standard No 1 from the requirement to produce a cash flow statement on the grounds that it is a small company.

1.2 Compliance with accounting standards

The financial statements are prepared in accordance with applicable United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice), which have been applied consistently.

1.3 Investments

Fixed asset investments are stated at cost less provision for diminution in value.

1.4 Deferred taxation

In accordance with Financial Reporting Standard 19 'Deferred tax', deferred tax is recognised in respect of all timing differences that have originated but not reversed by the balance sheet date. Provision is made at the rates expected to apply when the timing differences reverse.

Timing differences are differences between the company's taxable profits and its results as stated in the financial statements that arise from the inclusion of gains and losses in taxable profits in periods different from those in which they are recognised in the financial statements.

A net deferred tax asset is regarded as recoverable and therefore recognised only when, on the basis of all available evidence, it can be regarded as more likely than not that there will be suitable taxable profits from which the future reversal of the underlying timing differences can be deducted.

2 Fixed assets

	Investments £
Cost	
At 1 July 2013 & at 30 June 2014	145,080
At 30 June 2013	145,080

Based on the market value of the investments at the year end, the company would have a tax liability of approximately £3,800 if the investments were disposed of.

3 Share capital

	2014 £	2013 £
Allotted, called up and fully paid		
6 Ordinary shares of £1 each	6	6

EMESS BIOSCIENCES LIMITED

NOTES TO THE ABBREVIATED ACCOUNTS (CONTINUED)

FOR THE YEAR ENDED 30 JUNE 2014

4 Ultimate parent company

The ordinary shares are owned by six shareholders. No one shareholder holds more than 17% of the shares and are not entitled to exercise control or control the exercise of more than 50% of the voting power. Therefore there is no one controlling shareholder.